Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options.

By L. Maragakis, Trish Perl. Clinical Infectious Diseases, 2008

828 citations recorded by the source corpus.

Subfields: Endocrinology, Molecular Medicine, Pharmacology

View Paper: https://www.semanticscholar.org/paper/2a712a3b5cfa25419d69d61bc0a056beffdab5ae

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology

1. Robert A. Bonomo

In Molecular Medicine

1. Robert A. Bonomo
2. N. Indrawattana
3. Sirijan Santajit

In Pharmacology

1. Robert A. Bonomo

Citations in the corpus

• Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. (2009, background): “Recent studies of patients in the intensive care unit who had BSI and burn infection due to carbapenem-resistant Acinetobacter species demonstrate an increased mortality (crude mortality, 26%–68%), as well as increased morbidity and length of stay in the intensive care unit [75].”
• Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges (2016, background): “Based on surveillance studies from hospital networks, the frequency is similar in ICUs across Europe and Latin America (28–32).”